XOMA Royalty Corp (XOMA): M&A transaction — XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms

XOMA Royalty Corp

XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.
EGFRd2 (PF-8046052) outlicensed to Pfizer; potential milestones up to ~$650M; Phase 1 trial expected to complete 2029/2030.
JNJ-89853413 outlicensed to Janssen; potential milestones up to ~$195M; Phase 1 started Jan 2025, expected completion Aug 2028.
CVRs issued for 75% of net proceeds from future asset sales; XOMA valued CVRs at $0.00 due to early-stage uncertainty.
XOMA will use commercially reasonable efforts for 2 years to sell or license the legacy assets for CVR holders.

item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).

Action: acquisition
Counterparty: LAVA Therapeutics N.V.
Closing: 2025-11-20

Exact text from the filing

XOMA acquired LAVA's EGFRd2 (PF-8046052), JNJ-89853413 and LAVA-1266 legacy assets

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-033771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.